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Abstract
Background: Classic Kaposi’s Sarcoma (cKS) is a rare vascular tumor associated with Human Herpesvirus 8 (KSHV)
infection, nevertheless not all KSHV-infected individuals have cKS.
Objective: We investigated whether particular KIR/HLA receptor/ligand genotypes would be preferentially present
in KSHV-infected and uninfected individuals who have or have not developed cKS.
Methods: KIR/HLA genotypes were analyzed by molecular genotyping in 50 KSHV-infected individuals who did or
did not have cKS and in 33 age-and sex-matched KSHV seronegative individuals.
Results: There was no association of individual KIR, HLA or receptor ligand combinations with KSHV infection.
However, activating KIR and KIR/HLA genotypes were significantly more frequent in cKS cases, specifically KIR3DS1,
KIR2DS1, and KIR2DS1 with its HLA-C2 ligand.
Conclusion: A nonspecific inflammatory response triggered by activation of NK cells upon KIR-HLA interaction
could be associated with the pathogenesis of KS.
Keywords: Kaposi’s Sarcoma, Human Herpesvirus 8, KSHV, NK cells, KIR, HLA
Findings
Classic Kaposi’s Sarcoma (cKS) is a rare vascular neoplasm
of the skin related to Kaposi’s Sarcoma-associated Herpes
Virus (KSHV or Human Herpes Virus 8, HHV-8) infec-
tion. KSHV plays a prominent role in the progression of
cKS from an angio-proliferative disorder to sarcoma,
KSHV infection is nevertheless not sufficient to provoke
such progression as not all KSHV-infected individuals
develop cKS [1]. Natural killer (NK) cells are central
components of the innate immune response against viral
infections and tumour growth via direct and indirect
mechanisms [2]. The modulation of NK activity is a com-
plex and multi factorial phenomenon triggered by the
binding of inhibitory or activating killer cell immunoglo-
bulin-like receptors (KIR) to class I human leukocyte anti-
gens (HLA) [3,4]. When HLA molecules bind activating
KIR receptors, a potent inflammatory response finalized at
NK cell-mediated destruction of target cells, including
transformed tumor cells and virus-infected cells, is
stimulated [5]. KIR and HLA loci are highly polymorphic
and map in distinct human chromosomes (chromosomes
19 and 6, respectively); both KIR and the specific HLA
ligands must be present in order to regulate NK cell activ-
ity, such that one without the other is functionally inert.
We verified whether particular KIR/HLA genotypes
would be preferentially present in KSHV-infected and
uninfected individuals who do or do not develop cKS.
We studied eighty-three Caucasian individuals born
and living in Northern Italy; 50 of these individuals were
KSHV-infected (KSHV
pos). Histologically-confirmed cKS
had been diagnosed in 32 patients (cKS
pos)(23 male,
9 female, mean age: 71.1 ± 7.7 years); KSHV-infection
without tumour was observed in 18 other patients.
(KSHV
pos/cKS
neg)(8 male, 10 female, mean age: 83.4 ±
11.6 years). Thirty-three KSHV-uninfected individuals
(KSHV
neg)(24 male, 9 female, mean age: 70.0 ± 12.6
years) were also enrolled. Subjects did not suffer from
any disease that could potentially bias the analysis out-
come. KSHV-infected patients were enrolled, upon sign-
ing an informed consent approved by the Institutional
Review Board, by the Dermatology Unit of the Ospedale
* Correspondence: mario.clerici@unimi.it
1Don C. Gnocchi Foundation ONLUS, P. le Morandi 6, 20121 Milan, Italy
Full list of author information is available at the end of the article
Guerini et al. Infectious Agents and Cancer 2012, 7:9
http://www.infectagentscancer.com/content/7/1/9
© 2012 Guerini et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Maggiore Policlinico, in Milan. Controls subjects were
elderly healthy individuals seen at the Don Gnocchi
Foundation in Milan.
We analyzed antibodies against latent and lytic KSHV
antigens using an in-house immunofluorescence assay
(IFA) based on the body-cavity B cell lymphoma (BCBL-
1) cell line [6] as previously described [7]. Monoclonal
antibodies to ORF73 (LNA-1), ORF 59, and ORF K8.1
lytic proteins (Advanced Biotechnologies Inc., Maryland,
USA) were utilized as fluorescent controls. Sera contain-
ing antibodies for both latent and lytic antigens were
considered positives (KSHV
pos).
We performed molecular genotyping of HLA B (22
alleles), Cw (14 alleles), and KIR (18 genes) by PCR on
g e n o m i cD N Au s i n gs e q u e n c es p e c i f i cp r i m e r s( S S P )
according to the manufacturer’si n s t r u c t i o n s( B A G -
Lich, Germany, Astra Formedic, Milan Italy). Alleles
detection was done after amplification in a GeneAmp
PCR 9700 thermocycler (Applied Biosystem, Foster City,
CA, USA) by gel electrophoresis on 2% agarose gel.
KIR haplotype and ligands. Two broad haplotypes,
termed A and B, were defined based on KIR genes.
A and/or B haplotypes were classified based on the
criteria adopted by Middleton http://www.allelefre-
quencies.net[8].
Ligands group was defined as follows:
i. KIRs 2DL1 and 2DS1 bind the C2 epitope (Aspar-
agine at position 77, Lysine at position 80).
ii. KIRs 2DL2, 2DL3 and 2DS2 bind the C1 epitope
(Serine at position 77, Asparagine at position 80).
iii. HLA-Bw4 and the HLA-Bw4*80I (Isoleucine at
position 80) subset were considered the ligand for
KIR 3DL1 and 3DS1 [9,10].
We assessed differences between groups by the chi-
square test for categorical variables. P value with Yates
correction (py)o rF i s h e re x a c tt e s t( p f) and Bonferroni
correction for multiple test (pc) were applied. The asso-
ciation of each polymorphism with disease (cKS) was
measured by the Odd Ratio (OR) and a 95% Confidence
Interval (95%CI). For each independent variable, crude
and adjusted odds ratios and 95% confidence intervals
were calculated.
Multivariate analysis were performed with binary logistic
regression model to assess KIR-HLA genotypes associated
with cKS, considering cKS
pos versus cKS
neg as dependent
variable, gender and age as covariates. Analyses were car-
ried out using a SPSS 16.0 for Windows.
KIR gene distribution was evaluated in the three
groups studied (Additional file 1: Table S1); no
significant difference was detected between KSHV
pos/
cKS
neg infected and KSHV
neg individuals.
Because distribution of KIR and HLA genotypes were
similar between the two control groups, we thought it
was appropriate to combine them in subsequent
analyses.
Evaluations focusing on these two groups showed the
presence of higher frequencies of activating KIR genes
(Figure 1, Panel a) and of activating KIR/HLA receptor/
ligand genotypes (Figure 1, Panel b) in KSHV
pos/cKS
pos
patients compared to subjects without cKS.
A higher frequency of KIR2DS1+ and KIR2DS1+/C2+
genotypes was detected in cKS
pos compared to cKS
neg
individuals (py = 0.008; OR: 3.82) in KIR2DS1+ which
increases to 4,25 in KIR2DS1+/C2+ cKS patients (Table
1). The association between the KIR2DS1+/C2+ geno-
type and cKS was confirmed after binary logistic regres-
sion analysis adjusted for age and gender (p = 0.004 OR:
5.2, (95%) IC:1.7-16.3).
The frequency of KIR3DS1 gene distribution was quite
similar to that of KIR2DS1, probably due to their link-
age disequilibrium (LD).
Additionally, the activating KIR3DS1+ gene was statis-
tically more frequent in cKS
pos compared to cKS
neg indi-
viduals (py = 0.006; OR:4.00).
HLA-Bw4 molecules are ligands of KIR3DL1 and
KIR3DS1, particularly Bw4*80I (bearing an Isoleucine at
position 80) [11] showed a stronger binding affinity with
KIR3D alleles, therefore both KIR3DS1+/Bw4+ and
KIR3DS1+/Bw4*80I + genotypes distributions were ana-
l y s e d( T a b l e1 ) .H o w e v e rt h ef r e q u e n c yo fK I R 3 D S 1 +
/Bw4+ as well as KIR3DS1+/Bw4*80I + genotypes in
cKS
pos compared to cKS
neg subjects did not reach the
statistical significance (py > 0.05). Conversely, KIR3DS1
+/Bw4*80I- frequency resulted still statistically higher in
c K St h a ni nc o n t r o l s( p y = 0.006; OR:6.00), confirming
that the KIR3DS1 positivity, but not the KIR/HLA
receptor/ligand combination 3DS1/Bw4*80I, was asso-
ciated to cKS.
Finally KIR2DS2 gene and KIR2DS2/C1+ genotypes
were quite equally distributed in all the studied groups.
The frequencies of HLA ligands: HLAC2 + (C2/C2; C2/
C1), HLA C1 + (C1/C1; C2/C1), HLA Bw4+ (Bw4+/Bw4+,
Bw4+/Bw4-) and Bw4*80I + (Bw4*80I+/Bw4*80I+,
Bw4*80I +/Bw4*80I-) are shown in Table 1. No statistical
differences were observed between groups, revealing that
differences observed for KIR 2DS1+/C2+ was likely due to
the KIR/HLA receptor/ligand interaction and not to either
KIR or to HLA genes separately.
Finally, no differences were observed in the genotype
distribution of the other examined inhibitory and acti-
vating KIR genes (Additional file 1: Table S1) or in the
frequency of HLA-B and HLA-Cw alleles (not shown).
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Page 2 of 5In this work we investigated whether specific KIR genes
and their HLA class I ligands would be associated with
classic Kaposi sarcoma in KSHV
pos infected subjects.
Results herein, albeit stemming from analyses performed
in a limited number of individuals, indicate that a statisti-
cally higher frequency of activating KIR genes together
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Figure 1 Panel a: KIR gene distribution in KSHV-infected patients with classic Kaposi Sarcoma (cKSpos N = 32), and in age-matched
healthy KSHV-infected or uninfected individuals (cKSneg N = 51). Panel b: Functional KIR-HLA receptor/ligand genotypes in the same
individuals. *p = 0.01.
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Page 3 of 5with their HLA ligands is present in KSHV-infected
patients who have cKS compared to individuals including
those with KSHV infection without cKS
Importantly, whereas activating KIR genes were more
frequent in cKS patients, the distribution of KIR genes
was similar between KSHV
pos and KSHV
neg healthy con-
trols; this allowed us to combine them in a single control
group. The KIR2DS1+ and KIR3DS1+ genes were preva-
lent in cKS patients; This similarity of distribution may
be secondary to the fact that these genes are in linkage
disequilibrium. However, whereas the activating
KIR2DS1+/C2+ genotype was positively associated with
cKS development, HLA ligand distribution did not reveal
any statistical association with cKS. This observation,
together with the fact that the OR of KIR2DS1 associa-
tion increased when the KIR2DS1+/C2+ genotype was
evaluated, may suggest that the association of KIR2DS1
+/C2+ with cKS is mostly due to KIR-HLA interaction
and not to either KIR or to HLA genes separately.
Data herein indicate that a KIR/HLA “activating
milieu” is present in cKS; such milieu may be a risk fac-
tor for the development of this tumor. Our results add
cKS to the list of virus-associated cancers including cer-
vical neoplasia [12,13] and nasopharyngeal carcinoma
[14] where an increased presence of activating KIR/HLA
receptor/ligand combinations is observed and is sug-
gested to play a role in oncogenesis.
Genotypes that increase the activation of NK cells are
possibly beneficial in viral infections such as HIV and
HCV [15]; inflammatory components associated with
NK cell activation might nevertheless have a detrimental
effect, possibly facilitating the oncogenic process for
cancers that, as is the case with cKS, have an inflamma-
tory component [11,16]. Thus, the elicitation of inflam-
mation and NK cells activity via KIR/HLA interactions
might be directly involved in malignant transformation
and tumor progression as a consequence of the produc-
tion of cytokines such as TNF-a,I L - 6 ,a n dT G F - b that
contribute to the proliferation and survival of tumor
cells [17]. Non-specific inflammatory responses, such as
oxidative DNA damage, may be triggered by activated
NK upon KIR-HLA interaction as well, possibly facilitat-
ing the growth of oncogenic viruses [18].
The small sample size is a significant limitation of this
study. We tried to bypass this problem by sampling
together KSHV-infected and -uninfected healthy indivi-
duals, once we verified that the distribution of KIR and
HLA molecules was comparable.
It is important to underline that these data stem from
analyses performed in a relatively small group of indivi-
duals and will need to be validated using bigger cohorts
of KS patients.
Additional material
Additional file 1: Table S1. Inhibitory and activating KIRs genotype
distribution in 32 classic Kaposi sarcoma (cKS
pos), 18 KSHV-infection
without Ks (KSHV
pos/cKS
neg) and in 33 KSHV-uninfected individuals
(KSHV
neg).
Table 1 Activating KIRs and Kir/HLA receptor/ligand genotypes distribution in 32 classic Kaposi Sarcoma (cKS
pos), and
in 51 cKS
neg (18 KSHV-infected plus 33 KSHV-uninfected) individuals
KIR/KIR-ligands cKS
pos cKS
neg P value OR (95%CI)
N/T % N/T %
2DS1+ 21/32 (65.6) 17/51 (33.3) py = 0.008 3.82 (1.4-10.9)
2DS1+/C2+ 17/26 (65.4) 12/39 (30.7) py = 0.01 4.25 (1.3-14.2)
2DS1+/C2- 4/6 (66.7) 5/12 (41.7) pf = 0.62 ND
2DS2+ 27/32 (84.4) 31/51 (60.8) py = 0.04 3.48 (1.0-12.3)
2DS2+/C1+ 18/22 (81.8) 21/38 (56.7) py = 0.09 3.43 (0.9-14.9)
2DS2+/C1- 9/10 (90.0) 10/14 (71.4) pf = 0.36 ND
3DS1+ 20/32 (62.5) 15/51 (29.4) py = 0.006 4.00 (1.4-11.4)
3DS1+/Bw4+ 11/18 (61.1) 10/32 (31.2) py = 0.08 3.46 (0.9-13.9)
3DS1+/Bw4*80I+ 6/11 (54.5) 7/19 (36.8) py = 0.45 2.06 (0.4-12.3)
3DS1+/Bw4- 9/14 (64.3) 5/19 (26.3) py = 0.68 5.04 (0.9-30.6)
3DS1+/Bw4*80I- 14/21 (66.6) 8/32 (25.0) py = 0.006 6.00 (1.5-24.6)
HLA C2+ 26/32 (81.2) 39/51 (76.5) py = 0.80 1.33 (0.4-4.6)
HLA C1+ 22/32 (68.7) 37/51 (72.5) py = 0.90 0.83 (0.3-2.4)
HLA Bw4 18/32 (56.3) 32/51 (62.7) py = 0.72 0.76 (0.3-2.1)
HLA Bw4*80I+ 11/32 (34.4) 19/51 (37.5) py = 0.97 0.88 (0.3-2.5)
N/T: Number of subjects/Total subjects; (%) percentage in brackets;: py = p value with Yate’s correction,: pf = p value calculated with fisher exact test for small
number; OR: Odds ratio, IC: Interval of confidence
HLA C2 + (C2/C2; C2/C1), HLA C1 + (C1/C1; C2/C1), HLA Bw4 (Bw4+/Bw4+, Bw4+/Bw4-)
HLA Bw4*80I+ (Bw4*80I+/Bw4*80I+, Bw4*80I+/*Bw4*80I-)
The statistically significant associations are marked in bold
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